BJA FY25 Harold Rogers Prescription Drug Monitoring Program | O BJA 2025 172445

FAQs: BJA FY25 Harold Rogers Prescription Drug Monitoring Program (PDMP) Grant

What is the BJA FY25 Harold Rogers PDMP grant?

It is a discretionary grant funding opportunity from the U.S. Department of Justice, Bureau of Justice Assistance (BJA). The program focuses on strengthening how jurisdictions track and use prescription data related to controlled substances and certain other scheduled chemical products through a centralized prescription drug monitoring program (PDMP) database operated by an authorized agency.

What is the main purpose of this funding opportunity?

The core purpose is to improve the ability of regulatory agencies, law enforcement, and public health officials to collect, manage, and analyze prescription information through a centralized database. The goal is to better understand prescribing and dispensing patterns, identify potential diversion or misuse concerns, and support coordinated responses that protect public health and safety.

Which federal agency is offering this grant?

The grant is offered by the U.S. Department of Justice (DOJ), Bureau of Justice Assistance (BJA).

Is this a discretionary or formula grant?

This is a discretionary funding opportunity.

What is the Funding Opportunity Number for this program?

The Funding Opportunity Number is O-BJA-2025-172445.

What is the CFDA number and funding category?

The opportunity is listed under CFDA 16.754 and falls within the Law, Justice and Legal Services funding activity category.

What type of award is made under this opportunity?

Awards are made as grants.

Who is eligible to apply?

Eligible applicants include state governments, federally recognized Native American tribal governments, and Native American tribal organizations (including those other than federally recognized tribal governments).

Why are tribal organizations included as eligible applicants?

The eligibility reflects that PDMP administration and oversight responsibilities may sit with different governmental or tribally authorized bodies depending on the jurisdiction. The program is structured to allow those entities to build a centralized, authorized data capability that can serve multiple stakeholder groups.

What kinds of activities does the grant support?

The funding is structured to expand PDMP capacity and effectiveness, particularly around the quality, timeliness, and analytical usefulness of prescription monitoring data. While specific project types are not spelled out beyond the central goal, the emphasis on collection and analysis signals support for efforts such as maintaining or upgrading PDMP database infrastructure and improving how data is leveraged by authorized partners for oversight, investigations, and public health interventions.

What outcomes is this program trying to achieve?

The program aims to strengthen the data backbone and analytical capacity that supports better decision-making around controlled substance prescribing, enhances regulatory and enforcement tools against diversion, and helps public health officials monitor trends and target prevention and response efforts.

How many awards does BJA anticipate making?

BJA anticipates making about 15 awards.

What is the maximum award amount?

The award ceiling is up to $2,000,000 per award.

When is the application deadline?

The application deadline (original closing date) is October 27, 2025.

When was this opportunity created?

The opportunity was created on September 16, 2025.

What data does the PDMP focus on?

The PDMP focus described in the opportunity is on prescription data related to controlled substances and certain other scheduled chemical products.

How does a PDMP help law enforcement and regulatory agencies according to this notice?

By improving how prescription information is collected, managed, and analyzed in a centralized database, the PDMP can help identify prescribing and dispensing patterns and flag potential diversion or misuse concerns, supporting oversight and investigations.

How does a PDMP help public health officials according to this notice?

The strengthened collection and analysis of prescription monitoring data helps public health officials monitor trends and target prevention and response efforts, supporting coordinated actions that protect public health and safety.

Does the notice specify exact project types or required activities?

No. The notice does not spell out specific project types beyond the central goal of strengthening PDMP capacity and effectiveness, with emphasis on improving the quality, timeliness, and analytical usefulness of the data.

What does "centralized database operated by an authorized agency" mean in this context?

In this opportunity, it refers to a PDMP database that is centrally managed by an entity authorized within the jurisdiction to operate the system, enabling multiple stakeholder groups to rely on the same core prescription monitoring data resource for collection, management, and analysis.

What is the broader rationale for investing in PDMP capacity?

As described, the grant is intended as an investment in the infrastructure and analytical capability that improves understanding of prescribing and dispensing patterns, strengthens tools to address diversion, and supports coordinated public health and safety responses.